See more than ever before

The world’s most sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies
Detect relapse 200+ days earlier By detecting 1 part per million
See what others miss

Latest Updates

Oct 12, 2021

Lightning does strike twice: leveraging phased variants to enhance minimal residual disease detection

icon-download Download Review Paper

Sep 20, 2021

What’s Next for Liquid Biopsy Tests?

Jul 26, 2021

Foresight Diagnostics Commercializing PhasED-seq Liquid Biopsy Tech for Improved MRD Detection